Loading...
XPAR
BIM
Market cap14bUSD
Apr 07, Last price  
110.10EUR
1D
-4.01%
1Q
2.23%
Jan 2017
132.77%
Name

Biomerieux SA

Chart & Performance

D1W1MN
P/E
30.04
P/S
3.26
EPS
3.67
Div Yield, %
0.77%
Shrs. gr., 5y
—
Rev. gr., 5y
8.27%
Revenues
3.98b
+8.31%
993,600,0001,036,900,0001,062,800,0001,110,500,0001,223,400,0001,357,000,0001,427,200,0001,569,800,0001,587,900,0001,698,400,0001,964,600,0002,103,199,9992,288,200,0002,421,300,0002,674,800,0003,118,200,0003,376,200,0003,589,100,0003,674,700,0003,979,900,000
Net income
432m
+20.86%
90,100,000105,300,00098,100,000130,000,000148,200,000160,000,000160,500,000134,400,000164,300,000134,900,000110,500,000179,100,000238,100,000256,600,000272,800,000404,400,000601,100,000452,400,000357,600,000432,200,000
CFO
667m
+49.82%
164,500,000124,600,000188,700,000197,900,000188,600,000199,000,000216,600,000258,500,000240,500,000298,300,000310,000,000335,600,000341,300,000399,800,000407,900,000582,800,000824,700,000475,100,000445,400,000667,300,000
Dividend
Jun 09, 20250.9 EUR/sh
Earnings
May 23, 2025

Profile

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
URL
https://www.biomerieux.fr/
IPO date
Jun 07, 2004
Employees
12,557
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,979,900
8.31%
3,674,700
2.38%
3,589,100
6.31%
Cost of revenue
3,353,700
3,098,000
3,029,300
Unusual Expense (Income)
NOPBT
626,200
576,700
559,800
NOPBT Margin
15.73%
15.69%
15.60%
Operating Taxes
154,300
114,500
109,700
Tax Rate
24.64%
19.85%
19.60%
NOPAT
471,900
462,200
450,100
Net income
432,200
20.86%
357,600
-20.95%
452,400
-24.74%
Dividends
(100,200)
(100,200)
(101,200)
Dividend yield
0.82%
0.84%
0.87%
Proceeds from repurchase of equity
12,700
(14,200)
BB yield
-0.11%
0.12%
Debt
Debt current
163,400
187,000
Long-term debt
503,900
318,400
Deferred revenue
300
93,700
Other long-term liabilities
398,400
53,300
41,200
Net debt
(449,800)
94,700
(138,200)
Cash flow
Cash from operating activities
667,300
445,400
475,100
CAPEX
(345,800)
(338,300)
(286,700)
Cash from investing activities
(359,800)
(488,800)
(528,100)
Cash from financing activities
(212,600)
(122,300)
(244,200)
FCF
312,100
64,400
110,000
Balance
Cash
449,800
352,400
552,600
Long term investments
220,200
91,000
Excess cash
250,805
388,865
464,145
Stockholders' equity
450,300
369,600
4,057,300
Invested Capital
4,358,595
3,954,600
3,676,355
ROIC
11.35%
12.11%
13.64%
ROCE
13.51%
13.30%
13.35%
EV
Common stock shares outstanding
118,736
118,802
118,441
Price
103.50
2.88%
100.60
2.74%
97.92
-21.60%
Market cap
12,289,203
2.83%
11,951,528
3.05%
11,597,703
-21.90%
EV
11,845,503
12,046,228
11,498,203
EBITDA
951,400
835,600
817,400
EV/EBITDA
12.45
14.42
14.07
Interest
4,900
4,400
4,100
Interest/NOPBT
0.78%
0.76%
0.73%